<?xml version='1.0' encoding='utf-8'?>
<document id="28756727"><sentence text="Effects of m-nisoldipine on the activity and mRNA expression of four CYP isozymes in rats."><entity charOffset="11-24" id="DDI-PubMed.28756727.s1.e0" text="m-nisoldipine" /></sentence><sentence text="1" /><sentence text=" For the first time, a systemic in vivo investigation was employed to evaluate the potential effects of m-nisoldipine on activities of rat cytochrome P450 enzymes (CYP1A2, CYP2C11, CYP2D1 and CYP3A1) by both cocktail probe drugs and the quantitative real-time reverse-transcription polymerase chain reaction (RT-qPCR)"><entity charOffset="104-117" id="DDI-PubMed.28756727.s3.e0" text="m-nisoldipine" /></sentence><sentence text=" 2" /><sentence text=" m-Nisoldipine-treated and blank control groups were respectively administered m-nisoldipine at the dosage of 2"><entity charOffset="79-92" id="DDI-PubMed.28756727.s5.e0" text="m-nisoldipine" /></sentence><sentence text="5, 5 and 12" /><sentence text="5 mg/kg and CMC-Na solution for 15 days consecutively, then they were given the probe drugs of caffeine, diclofenac, dextromethorphan and midazolam (all probes were 5 mg/kg) by p"><entity charOffset="95-103" id="DDI-PubMed.28756727.s7.e0" text="caffeine" /><entity charOffset="105-115" id="DDI-PubMed.28756727.s7.e1" text="diclofenac" /><entity charOffset="117-133" id="DDI-PubMed.28756727.s7.e2" text="dextromethorphan" /><entity charOffset="138-147" id="DDI-PubMed.28756727.s7.e3" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.28756727.s7.e0" e2="DDI-PubMed.28756727.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28756727.s7.e0" e2="DDI-PubMed.28756727.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28756727.s7.e0" e2="DDI-PubMed.28756727.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28756727.s7.e0" e2="DDI-PubMed.28756727.s7.e3" /><pair ddi="false" e1="DDI-PubMed.28756727.s7.e1" e2="DDI-PubMed.28756727.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28756727.s7.e1" e2="DDI-PubMed.28756727.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28756727.s7.e1" e2="DDI-PubMed.28756727.s7.e3" /><pair ddi="false" e1="DDI-PubMed.28756727.s7.e2" e2="DDI-PubMed.28756727.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28756727.s7.e2" e2="DDI-PubMed.28756727.s7.e3" /></sentence><sentence text="o" /><sentence text=" The blood samples were collected at different times for liquid chromatography coupled with mass spectrometry (LC-MS) analysis" /><sentence text=" The corresponding pharmacokinetic parameters were applied to evaluate the effects of m-nisoldipine on the four CYP isoforms in vivo"><entity charOffset="86-99" id="DDI-PubMed.28756727.s10.e0" text="m-nisoldipine" /></sentence><sentence text=" In addition, RT-qPCR was performed to determine the effects of m-nisoldipine on the mRNA expression of CYPs in rat liver"><entity charOffset="64-77" id="DDI-PubMed.28756727.s11.e0" text="m-nisoldipine" /></sentence><sentence text=" Results indicated that high dose and middle dose of m-nisoldipine showed significant effects on all four CYPs and CYP2C11, respectively"><entity charOffset="53-66" id="DDI-PubMed.28756727.s12.e0" text="m-nisoldipine" /></sentence><sentence text=" Moreover, for CYP2D1 and CYP1A2, there were no significant effects found at either low or middle dose of m-nisoldipine"><entity charOffset="106-119" id="DDI-PubMed.28756727.s13.e0" text="m-nisoldipine" /></sentence><sentence text=" 3" /><sentence text=" This study could provide not only experimental evidence for potential clinical application of m-nisoldipine but also a practical strategy for assessing CYP-mediated drug-drug interactions"><entity charOffset="95-108" id="DDI-PubMed.28756727.s15.e0" text="m-nisoldipine" /></sentence><sentence text="" /></document>